Brought to you by 
AZ and the Karolinska Institute create new research center for cardiometabolic and regenerative med development
30 Nov 2021
Executive Summary
Twice in one day, AstraZeneca PLC announced plans to boost the company’s drug development efforts for cardiometabolic diseases. The first was with Moderna Therapeutics, and the second, with long-time partner the Karolinska Institute, additionally focuses on regenerative medicine.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ and the Karolinska Institute create new research center for cardiometabolic and regenerative med development
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice